About two weeks after pulling down $32 million to fund its Phase III trial with the sulfonylhydrazine alkylating agent cloretazine in acute myelogenous leukemia, Vion Pharmaceuticals Inc. has reached agreement with the FDA on a special protocol assessment. (BioWorld Today) Read More
